|
Factors
|
n
|
3-year LC (%)
|
p value
|
n
|
3-year OS (%)
|
p value
|
|---|
|
Age (years)
| | |
0.44
| | |
0.80
|
|
<65
|
35
|
73.3
| |
24
|
58.3
| |
|
≥65
|
44
|
67.5
| |
26
|
69.2
| |
|
ECOG performance score
| | |
0.43
| | |
0.47
|
|
0–1
|
66
|
71.6
| |
40
|
70.0
| |
|
2
|
12
|
62.3
| |
9
|
33.3
| |
|
Stage of the primary tumor
| | |
0.98
| | |
0.43
|
|
Stage 1–2
|
20
|
69.4
| |
13
|
61.5
| |
|
Stage 3–4
|
57
|
70.9
| |
35
|
65.7
| |
|
Timing of SABR
| | |
0.04
| | |
0.42
|
|
First pulmonary metastasis
|
51
|
62.6
| |
33
|
72.7
| |
|
Second or third
|
28
|
90.9
| |
17
|
47.1
| |
|
Pre-SABR CEA level
| | |
<0.01
| | |
0.40
|
|
≤6
|
62
|
78.1
| |
39
|
64.1
| |
|
>6
|
10
|
0
| |
6
|
66.7
| |
|
GTV
| | |
0.01
| | |
0.02
|
|
≤1.5 mL
|
41
|
88.5
| |
25
|
68.0
| |
|
>1.5 mL
|
38
|
50.1
| |
25
|
60.0
| |
|
Radiation dose
| | |
0.14
| | |
0.12
|
|
≤48 Gy
|
56
|
64.6
| |
33
|
54.5
| |
|
60 Gy
|
23
|
84.0
| |
17
|
82.4
| |
|
LC
| | |
-
| | |
0.06
|
|
Yes
|
-
|
-
| |
39
|
66.7
| |
|
No
|
-
|
-
| |
11
|
54.5
| |
-
LC local control, OS overall survival, ECOG Eastern Cooperative Oncology Group, SABR stereotactic ablative body radiotherapy, CEA carcinoembryonic antigen, GTV gross tumor volume
